Related references
Note: Only part of the references are listed.A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer
A. Atmaca et al.
BRITISH JOURNAL OF CANCER (2013)
Vitamin B6 metabolism influences the intracellular accumulation of cisplatin
Lorenzo Galluzzi et al.
CELL CYCLE (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Lisa M. Coussens et al.
SCIENCE (2013)
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Sophie Viaud et al.
SCIENCE (2013)
The secret ally: immunostimulation by anticancer drugs
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Molecular mechanisms of cisplatin resistance
L. Galluzzi et al.
ONCOGENE (2012)
An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Laura Senovilla et al.
SCIENCE (2012)
Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer
Lorenzo Galluzzi et al.
CELL REPORTS (2012)
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Oliver Kepp et al.
CANCER AND METASTASIS REVIEWS (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Testicular germ cell tumors: pathogenesis, diagnosis and treatment
Christian Winter et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress
I. Martins et al.
ONCOGENE (2011)
Bioluminescent Orthotopic Mouse Models of Human Localized Non-Small Cell Lung Cancer: Feasibility and Identification of Circulating Tumour Cells
Pierre Mordant et al.
PLOS ONE (2011)
Contribution of the immune system to the chemotherapeutic response
Alison M. McDonnell et al.
SEMINARS IN IMMUNOPATHOLOGY (2011)
Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non-Small Cell Lung Cancer
Gregory A. Otterson et al.
CLINICAL CANCER RESEARCH (2010)
Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
Laurence Zitvogel et al.
CLINICAL CANCER RESEARCH (2010)
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
Chemotherapy induces ATP release from tumor cells
Isabelle Martins et al.
CELL CYCLE (2009)
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death
Theocharis Panaretakis et al.
EMBO JOURNAL (2009)
Cancer chemotherapy:: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity
Cedric Menard et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Medical treatment of advanced testicular cancer
Darren R. Feldman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
Chiun Hsu et al.
LUNG CANCER (2008)
Molecular origins of cancer - Cancer immunology
Olivera J. Finn
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
Monitoring the trafficking of adoptively transferred antigen-specific CD8-positive T cells in vivo, using noninvasive luminescence imaging
Daejin Kim et al.
HUMAN GENE THERAPY (2007)
Murine models to evaluate novel and conventional therapeutic strategies for cancer
James E. Talmadge et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)
E. C. J. Phernambucq et al.
BRITISH JOURNAL OF CANCER (2006)
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N Casares et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development
LR Kelland
EUROPEAN JOURNAL OF CANCER (2004)
Cisplatin: mode of cytotoxic action and molecular basis of resistance
ZH Siddik
ONCOGENE (2003)
Quantitation of mitochondrial alterations associated with apoptosis
M Castedo et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2002)
Share Paper
